Update on the virologic and immunologic response to highly active antiretroviral therapy

Lisa Paula Jacobson, John P. Phair, Traci E. Yamashita

Research output: Contribution to journalArticle

Abstract

Highly active antiretroviral therapy (HAART) delays clinical progression by suppressing viral replication, measured by a substantial reduction in HIV RNA, allowing the immune system to reconstitute, measured in most studies by an increase in CD4 cells. These virologic and immunologic consequences do not occur uniformly among HAART users. Markers of HIV disease stage at the time of HAART initiation are critical determinants of the progression while receiving HAART. In this report, we review studies describing the heterogeneous virologic and immunologic progression after the initiation of HAART, discuss methodologic concerns in the study of the response of biomarkers, and update findings obtained in the Multicenter AIDS Cohort Study, which show that CD4 cell count, history of antiretroviral therapy, and age at the time of initiation are independent determinants of response.

Original languageEnglish (US)
Pages (from-to)325-332
Number of pages8
JournalCurrent Infectious Disease Reports
Volume6
Issue number4
StatePublished - Aug 2004

Fingerprint

Highly Active Antiretroviral Therapy
HIV
CD4 Lymphocyte Count
Immune System
Acquired Immunodeficiency Syndrome
Cohort Studies
Biomarkers
RNA

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Update on the virologic and immunologic response to highly active antiretroviral therapy. / Jacobson, Lisa Paula; Phair, John P.; Yamashita, Traci E.

In: Current Infectious Disease Reports, Vol. 6, No. 4, 08.2004, p. 325-332.

Research output: Contribution to journalArticle

@article{7951630b20224ad29a35824426982351,
title = "Update on the virologic and immunologic response to highly active antiretroviral therapy",
abstract = "Highly active antiretroviral therapy (HAART) delays clinical progression by suppressing viral replication, measured by a substantial reduction in HIV RNA, allowing the immune system to reconstitute, measured in most studies by an increase in CD4 cells. These virologic and immunologic consequences do not occur uniformly among HAART users. Markers of HIV disease stage at the time of HAART initiation are critical determinants of the progression while receiving HAART. In this report, we review studies describing the heterogeneous virologic and immunologic progression after the initiation of HAART, discuss methodologic concerns in the study of the response of biomarkers, and update findings obtained in the Multicenter AIDS Cohort Study, which show that CD4 cell count, history of antiretroviral therapy, and age at the time of initiation are independent determinants of response.",
author = "Jacobson, {Lisa Paula} and Phair, {John P.} and Yamashita, {Traci E.}",
year = "2004",
month = "8",
language = "English (US)",
volume = "6",
pages = "325--332",
journal = "Current Infectious Disease Reports",
issn = "1523-3847",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - Update on the virologic and immunologic response to highly active antiretroviral therapy

AU - Jacobson, Lisa Paula

AU - Phair, John P.

AU - Yamashita, Traci E.

PY - 2004/8

Y1 - 2004/8

N2 - Highly active antiretroviral therapy (HAART) delays clinical progression by suppressing viral replication, measured by a substantial reduction in HIV RNA, allowing the immune system to reconstitute, measured in most studies by an increase in CD4 cells. These virologic and immunologic consequences do not occur uniformly among HAART users. Markers of HIV disease stage at the time of HAART initiation are critical determinants of the progression while receiving HAART. In this report, we review studies describing the heterogeneous virologic and immunologic progression after the initiation of HAART, discuss methodologic concerns in the study of the response of biomarkers, and update findings obtained in the Multicenter AIDS Cohort Study, which show that CD4 cell count, history of antiretroviral therapy, and age at the time of initiation are independent determinants of response.

AB - Highly active antiretroviral therapy (HAART) delays clinical progression by suppressing viral replication, measured by a substantial reduction in HIV RNA, allowing the immune system to reconstitute, measured in most studies by an increase in CD4 cells. These virologic and immunologic consequences do not occur uniformly among HAART users. Markers of HIV disease stage at the time of HAART initiation are critical determinants of the progression while receiving HAART. In this report, we review studies describing the heterogeneous virologic and immunologic progression after the initiation of HAART, discuss methodologic concerns in the study of the response of biomarkers, and update findings obtained in the Multicenter AIDS Cohort Study, which show that CD4 cell count, history of antiretroviral therapy, and age at the time of initiation are independent determinants of response.

UR - http://www.scopus.com/inward/record.url?scp=4444358490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444358490&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 325

EP - 332

JO - Current Infectious Disease Reports

JF - Current Infectious Disease Reports

SN - 1523-3847

IS - 4

ER -